- 作者：Giuseppe Sanguineti ; MD&lowast ; ; sanguineti@ifo.it" class="auth_mail" title="E-mail the corresponding author ; Fabio Arcidiacono ; MD&lowast ; ; Valeria Landoni ; PhD&dagger ; ; Bianca Maria Saracino ; MD&lowast ; ; Alessia Farneti ; MD&lowast ; ; Stefano Arcangeli ; MD&lowast ; ; Maria Grazia Petrongari ; MD&lowast ; ; Sara Gomellini ; MD&lowast ; ; Lidia Strigari ; PhD&dagger ; ; Giorgio Arcangeli ; MD&lowast ;
- 刊名：International Journal of Radiation Oncology*Biology*Physics
- 出版年：2016
- 出版时间：1 October 2016
- 年：2016
- 卷：96
- 期：2
- 页码：304-312
- 全文大小：957 K
Methods and Materials
Patients with intermediate- to high-risk localized prostate cancer were treated with conformal RT and short-course androgen deprivation. Both the prostate and the entire seminal vesicles were treated to 80 Gy in 40 fractions over 8 weeks (CFRT) or 62 Gy in 20 fractions over 5 weeks (MHRT). The endpoint of the present study was the development of any episode or grade of macroscopic hematuria. The median follow-up period was 93 months (range 6-143).
Results
Macroscopic hematuria was reported by 25 of 168 patients (14.9%). The actuarial estimate of hematuria at 8 years was 17.0% (95% confidence interval [CI] 10.7%-23.3%). The number of patients with hematuria was 6 and 19 in the CFRT and MHRT arms, respectively, for an actuarial 8-year estimate of 9.7% and 24.3%, respectively (hazard ratio 3.468, 95% CI 1.385-8.684; P=.008). Overall, 8 of 25 patients were found to have biopsy-proven urothelial carcinoma (3 in the CFRT arm and 5 in the MHRT arm; P=.27). Thus, the 8-year actuarial incidence of macroscopic hematuria (after censoring urothelial cancer–related episodes) was 4.1% and 18.2% after CFRT and MHRT, respectively (hazard ratio 4.961, 95% CI 1.426-17.263; P=.012). The results were confirmed by multivariate analysis after accounting for several patient-, treatment-, and tumor-related covariates.
Conclusions
MHRT was associated with a statistically significant increased risk of macroscopic hematuria compared with CFRT.